PTC Therapeutics Grants 300 RSUs to Boost Workforce and Attract Talent

PTC Therapeutics Strengthens Workforce with Strategic RSU Grant

PTC Therapeutics, Inc. (NASDAQ: PTCT) announces the approval of 300 restricted stock units (RSUs) for a new non-executive employee, which takes effect January 2, 2026. This move aligns with PTC's ongoing strategy to attract and retain top talent within the biopharmaceutical industry. Each RSU grants the recipient the right to receive one share of common stock upon vesting, providing a performance-based incentive that fosters long-term commitment to the company. The Compensation Committee's endorsement of this inducement grant underscores PTC's dedication to building a motivated workforce that can drive the company’s innovative initiatives.

The RSUs will vest over a four-year period, with 25% becoming available each year on the anniversary of the hire date, contingent upon the new employee’s continued service at PTC. This structured vesting schedule not only incentivizes the new hire to remain with the company but also aligns their interests with those of PTC and its stakeholders. Such strategic compensation measures are critical in the competitive landscape of biopharmaceuticals, where attracting skilled professionals is essential for advancing the development of transformative therapies aimed at rare disorders.

As a global biopharmaceutical enterprise, PTC Therapeutics focuses on discovering, developing, and commercializing innovative medicines for individuals with unmet medical needs. The company’s diverse pipeline of therapies reflects its commitment to addressing critical healthcare challenges. By offering competitive compensation packages, including RSUs, PTC positions itself as an employer of choice within the industry, fostering a culture of innovation and dedication to patient care.

In addition to this significant workforce initiative, PTC Therapeutics continues to emphasize its role in enhancing access to advanced treatments for rare disorders. The company's scientific expertise and robust commercial infrastructure help maximize the value delivered to patients and stakeholders alike. For further insights into PTC’s mission and pipeline, interested parties are encouraged to explore the company’s website and social media channels.

For media inquiries, Jeanine Clemente is available to provide additional information, while Ellen Cavaleri can assist with investor-related questions.